nach oben

Tumor Biology

Erschienen in:

01.04.2014 | Research Article

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis

verfasst von: Weijie Zhu, Lei Lu, Yi Li, Jie Yao, Bainan Xu

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The potentially functional polymorphism Arg72Pro in p53 gene has been implicated in glioma risk, but published studies have mixed findings. The aim of current investigation was to identify whether p53 Arg72Pro polymorphism was significantly associated with the risk of glioma. By searching the databases of PubMed, EMBASE, and Web of Science, our meta-analysis included ten eligible studies consisting of 2,645 glioma cases and 3,920 control subjects. The association between p53 Arg72Pro polymorphism and glioma risk was assessed by summarizing the odds ratios (ORs) with the corresponding 95 % confidence intervals (CIs). We found that there was no overall risk of glioma in relation to any genetic model of p53 Arg72Pro polymorphism. Similar results were implicated in the analyses which are subgrouped by ethnicity and source of controls. This nonsignificant association remained stable when analyses were restrained to the studies consistent with HWE. In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk.

Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101(10):2293–9.PubMedCrossRef

Ron E et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319(16):1033–9.PubMedCrossRef

Thomas TL et al. Brain tumor mortality risk among men with electrical and electronics jobs: a case-control study. J Natl Cancer Inst. 1987;79(2):233–8.PubMed

Inskip PD, Linet MS, Heineman EF. Etiology of brain tumors in adults. Epidemiol Rev. 1995;17(2):382–414.PubMed

Bondy ML et al. Mutagen sensitivity and risk of gliomas: a case-control analysis. Cancer Res. 1996;56(7):1484–6.PubMed

Bondy ML et al. Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst. 2001;93(20):1553–7.PubMedCrossRef

Ruttan CC, Glickman BW. Coding variants in human double-strand break DNA repair genes. Mutat Res. 2002;509(1–2):175–200.PubMedCrossRef

Dasika GK et al. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene. 1999;18(55):7883–99.PubMedCrossRef

Wrensch M et al. The molecular epidemiology of gliomas in adults. Neurosurg Focus. 2005;19(5):E5.PubMedCrossRef

10.

Ehrlich M, Zhang XY, Inamdar NM. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytosine residues. Mutat Res. 1990;238(3):277–86.PubMedCrossRef

11.

Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001;114(Pt 23):4139–40.PubMed

12.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10.PubMedCrossRef

13.

Parhar P et al. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res. 2005;137(1–2):98–103.PubMedCrossRef

14.

Jin T, Zhang J, Li G, Li S, Yang B, Chen C, et al. TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population. Cancer Biother Radiopharm. 2013;28(3):248–53.PubMedCrossRef

15.

Malmer BS et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82(3):229–37.PubMedCrossRef

16.

El HS et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology. 2009;72(4):332–6.CrossRef

17.

Wang LE et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64(16):5560–3.PubMedCrossRef

18.

Rajaraman P et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1655–61.PubMedCrossRef

19.

Idbaih A et al. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008;1198:16–20.PubMedCrossRef

20.

Pinto GR et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res. 2008;7(1):207–16.PubMedCrossRef

21.

Lima-Ramos V et al. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008;180(1):14–9.PubMedCrossRef

22.

Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRef

23.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed

24.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef

25.

Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRef

26.

Idbaih A et al. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Cancer Genet Cytogenet. 2007;176(2):121–6.PubMedCrossRef

27.

Faria MH et al. TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression. APMIS. 2012;120(11):882–9.PubMedCrossRef

28.

Portwine C et al. Absence of germline and somatic p53 alterations in children with sporadic brain tumors. J Neurooncol. 2001;52(3):227–35.PubMedCrossRef

29.

Koopmann J et al. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer. 1995;72(5):1230–3.PubMedCentralPubMedCrossRef

30.

Iijima, J., et al., [Detection of codon 72 polymorphism of p53 gene from blood and loss of heterozygosity in brain tumors using polymerase chain reaction]. No To Shinkei, 1993. 45(1): p. 43-7.

31.

Zawlik I et al. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol. 2009;19(2):188–94.PubMedCrossRef

32.

Jha P et al. TP53 polymorphisms in gliomas from Indian patients: study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp Mol Pathol. 2011;90(2):167–72.PubMedCrossRef

33.

Shete S et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41(8):899–904.PubMedCrossRef

34.

Wrensch M et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905–8.PubMedCentralPubMedCrossRef

35.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-8.

36.

Shi M et al. TP53 codon 72 polymorphism and glioma risk: a meta-analysis. Oncol Lett. 2012;3(3):599–606.PubMedCentralPubMed

37.

Malmer B et al. p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2220–3.PubMedCrossRef

38.

He F et al. P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis. Tumor Biol. 2013;34:3121–30.CrossRef

39.

Higgins J.P.T., Greens S., Cochrane handbook for systematic reviews of intervention version 5.1.0 [updated March 2011]. The Cochrane collaboration, 2011. Available from www.cochrane-handbook.org.Accessed 30 May 2013.

Titel: The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis
verfasst von: Weijie Zhu
Lei Lu
Yi Li
Jie Yao
Bainan Xu
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1494-4

Springer Medizin

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Haplotype-based case–control study of DNA repair gene XRCC3 and hepatocellular carcinoma risk in a Chinese population

Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients

Anti-hepatoma cells function of luteolin through inducing apoptosis and cell cycle arrest

The association between cytotoxic T lymphocyte-associated antigen-4 and cervical cancer

Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients

Astrocyte elevated gene-1: a novel independent prognostic biomarker for metastatic ovarian tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie